THE Department of Health (DoH) upheld on Thursday the permanent revocation of the certificates of product registration (CPRs) of Dengvaxia, the first vaccine against dengue.
The Health department said the Food and Drug Administration (FDA) revoked the CPRs because of the failure of French drug manufacturer Sanofi Pasteur to submit post-approval requirements.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.